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Abstract
Background: Many patients with end-stage renal disease use a central venous catheter for hemodialysis access. A large majority
of these catheters malfunction within one year of insertion, with up to two-thirds due to thrombosis. The optimal solution for
locking the catheter between hemodialysis sessions, to decrease the risk of thrombosis and catheter malfunction, is unknown.
The Prevention of Catheter Lumen Occlusion with rt-PA versus Heparin (PreCLOT) study will determine if use of weekly rt-
PA, compared to regular heparin, as a catheter locking solution, will decrease the risk of catheter malfunction.
Methods/Design: The study population will consist of patients requiring chronic hemodialysis thrice weekly who are dialyzed
with a newly inserted permanent dual-lumen central venous catheter. Patients randomized to the treatment arm will receive rt-
PA 1 mg per lumen once per week, with heparin 5,000 units per ml as a catheter locking solution for the remaining two sessions.
Patients randomized to the control arm will receive heparin 5,000 units per ml as a catheter locking solution after each dialysis
session. The study treatment period will be six months, with 340 patients to be recruited from 14 sites across Canada. The
primary outcome will be catheter malfunction, based on mean blood flow parameters while on hemodialysis, with a secondary
outcome of catheter-related bacteremia. A cost-effectiveness analysis will be undertaken to assess the cost of maintaining a
catheter using rt-PA as a locking solution, compared to the use of heparin.
Discussion: Results from this study will determine if use of weekly rt-PA, compared to heparin, will decrease catheter
malfunction, as well as assess the cost-effectiveness of these locking solutions.
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Background
In Canada approximately 5 to 40% of hemodialysis
patients utilize a central venous catheter for vascular
access for hemodialysis [1]. The major complications of
these catheters include infection, thrombosis, and poor
blood flow resulting in inadequate hemodialysis. Approx-
imately fifty percent of hemodialysis catheters fail within
one year of insertion [2,3], with up to two-thirds second-
ary to thrombosis [4,5].
Inter-dialytic catheter locking with variable concentra-
tions of heparin, usually based on the catheter priming
volume [6], is commonly undertaken to prevent throm-
bosis. The evidence to guide the use of specific locking
solutions, including the strength and amount of solution,
is limited. Even the National Kidney Foundation Dialysis
Outcomes Quality Initiative (K-DOQI) guidelines for vas-
cular access do not provide recommendations for the
locking of catheters to prevent thrombosis during the
interdialytic period [7].
The critical care medicine and oncology literature have
provided some evidence for the use of prophylactic anti-
coagulant catheter locking solutions to decrease catheter-
related thrombosis. While a meta-analysis suggested
heparin reduced thrombus formation [8], the heparin
dose utilized was extremely variable, ranging from 5,000
units every 12 hours to a continuous infusion of 1 unit/
mL (combined with an infusion of total parenteral nutri-
tion). The generalizability of these results to hemodialysis
catheters which are larger in size, utilized for longer peri-
ods, and require a solution to remain in-situ for up to 72
hours, is questionable.
A few studies have attempted to determine if citrate and
heparin have equal efficacy in maintaining hemodialysis
catheter patency [9-11], however these studies are limited
by their small sample sizes, short follow-up period, and
surrogate outcome measures of catheter-related thrombo-
sis prone to measurement error. A recent study comparing
citrate 30% and heparin reported no differences in cathe-
ter flow problems and thrombosis, however there was a
significant reduction in catheter related bacteremia for the
citrate arm [12]. Conclusions regarding superiority, or
even equivalency, of heparin and citrate for catheter pat-
ency can not be made based on the available evidence.
More recently tissue plasminogen activator (rt-PA) has
been used in the treatment of catheter-related thrombosis
[13-16], and has also been considered as a possible lock-
ing solution for the primary prevention of catheter mal-
function. Rt-PA preferentially binds to fibrin and thus
activates plasminogen in close proximity to the clot,
which confines fibrinolysis to the formed thrombus and,
in theory, avoids systemic activation. Using a randomized
crossover design with 12 patients, Schenk and colleagues
[17] demonstrated that use of 2 mg of rt-PA per catheter
lumen at the end of each hemodialysis session was supe-
rior to the conventional practice of locking each lumen
with 2000 units of heparin. After four months, 20% of the
heparin locked catheters had a thrombotic event versus
0% in the rt-PA group. While the results of this study are
encouraging with respect to rt-PA as a catheter locking
solution, the small sample size and single centre enrol-
ment limit the study generalizability and the ability to
change clinical practice based on these results. In addi-
tion, the cost of using rt-PA after each dialysis session may
out-weigh the potential benefit.
The optimal frequency of instillation and dose of rt-PA in
the primary prevention of catheter malfunction is
unknown. In the study by Schenk et al [17] the dose of rt-
PA was 2 mg per lumen (information regarding luminal
volume was not provided), instilled after each dialysis ses-
sion. It may be possible that a smaller dose, such as 1 mg
per lumen, or less frequent administration, such as once
every week, may result in a decreased incidence of catheter
malfunction when compared to the standard instillation
of heparin, at a more reasonable cost.
In addition to thrombosis, catheter-related bacteremia is a
serious complication of catheter use, with a reported inci-
dence of 2.5 to 6.5 episodes per 1000 catheter-days [18-
21]. Several mechanisms are believed to contribute to
catheter-related bacteremia, including the formation of an
intraluminal thrombosis which may act as a nidus for bac-
terial biofilm development on the catheter [22,23]. While
antibiotic locking solutions have been proposed as a
method to treat (.([24], as well as prevent [25], catheter-
related bacteremia, their side effects limit their wide-
spread use [26]. It is plausible that use of a locking solu-
tion which decreases the rate of thrombus formation con-
sequently may also decrease the rate of catheter-related
bacteremia [26].
Evidence to date supports the safety profile of rt-PA as a
catheter locking solution. Rt-PA is rapidly cleared from
the plasma (mediated primarily by the liver), with an ini-
tial half life of less than 5 minutes. The dose of rt-PA most
extensively studied for treatment of catheter malfunction
is 2 mg per lumen, and at these doses systemic fibrinogen
levels [27], platelet count, plasminogen level, fibrin deg-
radation products, INR and PTT results all remain
unchanged [28]. Two of the largest studies to date of rt-PA
use in non-dialysis catheters, which included over 1,000
patients, reported no cases of death, major bleeding epi-
sodes, or embolic events attributable to treatment [29,30].
The dose of rt-PA in these studies was 2 mg with a dwell
time of up to 2 hours, with a second 2 mg dose adminis-BMC Nephrology 2006, 7:8 http://www.biomedcentral.com/1471-2369/7/8
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tered if function was not restored [29,30]. Thus at low
doses rt-PA appears to have relatively few adverse effects.
In summary, the evidence to guide selection of the opti-
mal catheter locking solution in the primary prevention of
catheter malfunction is limited. While preliminary data
[17] would suggest rt-PA may be an effective locking solu-
tion, the optimal dose and frequency of administration
are unknown. The Prevention of Catheter Lumen Occlu-
sion with rt-PA versus Heparin (PreCLOT) study will com-
pare the use of rt-PA versus heparin in the primary
prevention of hemodialysis catheter malfunction.
Methods
Study aims
The primary objective of PreCLOT is to determine if sub-
stituting rt-PA (1 mg per lumen) for heparin once per
week as a catheter locking solution will decrease the inci-
dence of catheter malfunction, compared to locking with
heparin alone (5000 units per mL) after each hemodialy-
sis session. The secondary objective is to determine if sub-
stituting rt-PA (1 mg per lumen) for heparin once per
week as a locking solution will decrease the incidence of
catheter-related bacteremia, compared to locking with
heparin alone after each hemodialysis session. An eco-
nomic evaluation of rt-PA versus heparin in the primary
prevention of catheter malfunction will also be con-
ducted.
Study design and setting
PreCLOT is a randomized controlled trial with blinding of
patients, health care providers, and all study staff and out-
come assessors. In this study hemodialysis patients with a
newly inserted permanent dialysis catheter are ran-
domised to receive rt-PA 1 mg per catheter lumen once per
week, with heparin 5,000 units per ml used as a locking
solution for the other two dialysis sessions, or heparin
5,000 units per ml (luminal volume) after each dialysis
session.
Ethical considerations
Ethical approval has been obtained in all study sites. Two
external bodies, a Data Safety Monitoring Board and a
Trial Steering Committee, will monitor study progress.
Study interventions
The intervention will be to lock the catheter with rt-PA at
a dose of 1 mg per lumen, once per week, with unfraction-
Table 1: Study inclusion and exclusion criteria
Inclusion criteria:
• End stage renal disease patients with newly inserted permanent, tunnelled, dual-lumen catheter
• Naïve to study but not naïve to catheters (both virgin and non-virgin catheters will be included)
• Expected to use catheter, and to dialyze at study centre, for at least six months
• Frequency of hemodialysis 3 times per week
• If indication for catheter was replacement for catheter related infection patients will be eligible after the infection has been treated and the patient 
has been off antibiotics for 3 hemodialysis sessions
• Patient or legal representative able to provide written consent
• Eighteen years of age or older
• Baseline INR ≤ 1.3
• Baseline platelet count ≥ 60 × 109/L
Exclusion criteria:
• Use of systemic anticoagulation (if indication for anticoagulation is catheter patency patients may be eligible if the systemic anticoagulation is 
discontinued and baseline INR is = 1.3)
• Insertion of a new permanent catheter by a guide-wire exchange procedure
• Insertion of a new permanent catheter into the femoral vein
• Current use of antibiotics for catheter-related bacteremia (see inclusion criteria above)
• Major hemorrhage in the prior 4 weeks, defined as bleeding resulting in a drop in hemoglobin of greater than 20 g/L or bleeding requiring 
transfusion of packed red blood cells with other clinical evidence or suspicion of bleeding
• History of intra-cranial bleed in the prior 4 weeks
• Intra-cranial or intra-spinal neoplasm (current)
• Allergy or intolerance to rt-PA or heparin or its constituents
• Active pericarditis – defined by the presence of a pericardial rub
• Weight ≤ 30 kg
• Patient pregnant or lactating
• Child bearing potential (i.e. pre-menopausal woman who is not using a reliable method of contraception)
• Major surgery in past 48 hours (CABG, organ biopsy, puncture of non-compressible vessels), or scheduled for major surgery during the study 
period
• Involvement in another randomized drug trial
• Presence of a fever as defined by a temperature > 38.2°CBMC Nephrology 2006, 7:8 http://www.biomedcentral.com/1471-2369/7/8
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ated heparin 5,000 units per ml used as a locking solution
for the other two dialysis sessions. Rt-PA will be adminis-
tered into each lumen initially, with saline added to "top-
up" the lock to the full luminal volume. To ensure that rt-
PA is administered to the catheter tip, the site of thrombus
formation, it will be instilled down each lumen followed
by normal saline to a volume adequate to fill the lumen.
The control arm will receive unfractionated heparin 5,000
units per ml, with a volume to fill the lumen, adminis-
tered after each dialysis session. The use of heparin is the
current standard of practice in most dialysis centres.
Identification of eligible patients
Eligible patients are hemodialysis patients with a newly
inserted permanent tunnelled catheter, including patients
who have had a catheter inserted for the first time (virgin)
as well as those who have had either a temporary or per-
manent catheter at some point in the past (non-virgin).
Given the potential for a higher patency rates for virgin
versus non-virgin catheters [13], patients will be stratified
by virgin vs non-virgin status. Inclusion and exclusion cri-
teria are outlined in Table 1.
Patient recruitment will occur over a two week period fol-
lowing catheter insertion, during which time centre spe-
cific catheter management will take place. The patient will
be eligible for randomization after the fourth hemodialy-
sis session, if sessions three and four were successful
(defined as a mean blood flow of ≥ 300 ml/min). The two
week eligibility period is included for two reasons: 1) the
risk of local bleeding following catheter insertion may be
slightly increased using a locking solution of heparin
5,000 units per ml, therefore catheter management during
the initial two week period will be at the discretion of the
study centre; and 2) catheter malfunction which occurs
within two weeks of insertion is more likely due to a
mechanical cause rather than thrombosis.
Randomization and study blinding
Following informed consent, patients will be randomized
in blocks of four, and stratified by study centre and virgin
versus non-virgin catheter status. The randomization
schedule has been developed and will be administered by
an independent trials unit. The pharmacy departments at
each study site will receive the randomization number
and treatment allocation via e-mail, and will prepare and
dispense the drug accordingly. The study investigators,
coordinators, patients, and all members of the research
team will be blinded to treatment allocation.
On treatment days the pharmacy will dispense four
syringes to the study patient, to maintain blinding. For
patients on the treatment arm these syringes will contain
rt-PA and saline (for the "top up"), numbered according
to order of instillation. To ensure blinding, patients in the
control arm will also be dispensed four syringes all of
which will contain heparin 5,000 units per ml. The vol-
ume of heparin used as the locking solution will be equal
to the luminal volume. All syringes will be labelled and
numbered by the pharmacy as to the order of instillation,
and will be identical in appearance. On non-treatment
days, heparin (5,000 units per ml, luminal volume), will
be prepared and administered by the hemodialysis nurse,
as per usual standard of care.
Primary outcome
The primary outcome is catheter malfunction, defined by
one of the following events occurring after attempts to re-
establish patency have been undertaken as per a pre-
defined protocol (including flushing the catheter with a
10 cc syringe, repositioning the patient and reversal of
lines):
• Peak blood flow ≤ 200 ml/min for 30 minutes during an
ongoing dialysis treatment (with maximum arterial and
venous pressure limits of -250 mmHg and +250 mmHg
respectively)
• Mean blood flow ≤ 250 ml/min during two consecutive
dialysis sessions, calculated as the blood processed in mil-
lilitres divided by the time on dialysis in minutes (with
maximum arterial and venous pressure limits of -250
mmHg and +250 mmHg respectively)
• Inability to initiate dialysis with no blood flow
According to the K/DOQI guidelines an extracorporeal
blood flow of ≥ 300 ml/min is required to provide ade-
quate dialysis [7]. A peak blood flow of ≤ 200 ml/min for
30 minutes, or a mean blood flow of ≤ 250 ml/min during
two consecutive dialysis sessions, were chosen to define
catheter malfunction as this blood flow will not permit
achievement of adequate dialysis. The blood flow must be
maintained with a maximum venous pressure of +250
mmHg and arterial pressure of -250 mmHg, to ensure
higher blood flows are not achieved at the expense of
excessive pressures. A blood flow which cannot be main-
tained with venous and arterial pressures of 250 mmHg
should be investigated for catheter malfunction.
Reversal of catheter lines may be required to initiate or
maintain dialysis during some sessions, however reversal
of lines over several sessions may lead to increased re-cir-
culation of blood and inadequate dialysis. The need for
ongoing reversal of catheter lines to maintain dialysis
would therefore suggest potential malfunction. A protocol
regarding catheter line reversal will be implemented to
ensure that ongoing line reversal is not undertaken, specif-
ically:BMC Nephrology 2006, 7:8 http://www.biomedcentral.com/1471-2369/7/8
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• Catheter lines may be reversed in an attempt to re-estab-
lish patency and initiate/maintain dialysis
• Catheter lines may be reversed for no more than three
consecutive dialysis sessions
• After three consecutive dialysis sessions with reversed
lines the next two consecutive sessions must be run with
lines in the straight position. Primary outcomes will then
be assessed
• Primary outcome criteria is the same during the period
of line reversal
• A dialysis session is considered to have included line
reversal if any portion of that run was undertaken with a
reversal of lines
Secondary outcome
Catheter-related bacteremia, the secondary outcome, will
be defined according to the Canadian definitions for cath-
eter-related infections [31], as outlined in Table 2. Both
"definite" and "probable" infections will constitute a
study outcome. These patients will remain in the study
and their catheter-related infection will be treated by the
attending staff nephrologist according to usual practice. If
a new catheter is clinically indicated the patient will be
censored at the time of catheter removal.
Data collection
A web-based electronic case report form (eCRF) for data
entry and ongoing communication and documentation
will be used. Baseline data and ongoing data collection, as
outlined in Table 3, will be obtained.
Patient follow-up procedures
Patients will be followed from trial entry until study com-
pletion (six month study period). The study coordinator
will review each patient and their hemodialysis records at
two week intervals and record primary or secondary end-
points. Patients who reach the primary outcome of cathe-
ter malfunction will also be followed for an additional
Table 2: Definitions for catheter-related bacteremia
Definite catheter-related bacteremia:
• Confirmation of septic thrombophlebitis with a single positive blood culture, or
• Single positive blood culture and positive culture of catheter segment with identical organism, or
• 10-fold colony count difference in blood cultures drawn from catheter and peripheral blood, or
• Single positive blood culture and positive culture from discharge or aspirate from exit site, tunnel, or pocket, with identical organism
Probable catheter-related bacteremia:
• Two or more positive blood cultures with no evidence for source other than catheter, or
• Single positive blood culture for S. aureus or Candida with no evidence for source other than catheter, or
• Single positive blood culture for coagulase negative staphylococci, Bacillus, Corynebacterium jeikeium, Enterococcus, Trichophyton, or Malassezia in 
immunocompromised or neutropenic host or in patients receiving TPN with no evidence for source other than catheter
Table 3: Baseline and ongoing data collection
Baseline data:
• age, sex, target weight, duration on dialysis, cause of renal failure
• type of catheter, insertion site, indication for catheter, history of rt-PA use or catheter replacement for malfunction
• details regarding previous catheter use
• history of deep vein thrombosis/pulmonary embolism
• baseline hemoglobin, platelets, albumin, Kt/V, urea reduction ratio (URR) and INR
• medication use
• comorbidities as defined by the Charlson Co-morbidity Index
• blood processed in millilitres
• time on dialysis (minutes)
• mean venous and arterial pressures
• number of dialysis set-ups (lines and membranes)
• mean intradialytic heparin dose
• weight loss
Monthly Laboratory Data:
• haemoglobin, platelets, albumin
• delivered dose of dialysis (Kt/V and URR)BMC Nephrology 2006, 7:8 http://www.biomedcentral.com/1471-2369/7/8
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one month period, or until either: 1) six consecutive suc-
cessful hemodialysis sessions are achieved (defined as a
mean blood flow of ≥ 300 ml/min at each run in the two
week period), or 2) the catheter is removed. Extending the
follow-up will enable documentation of the natural his-
tory of the catheter after an episode of malfunction, and
will allow an assessment of the costs associated with
maintaining patency for the economic analysis. A time
period of six successful hemodialysis sessions was chosen
as recurrent malfunction typically occurs within two
weeks of the initial malfunction [13]. Study drug may be
discontinued for reasons of patient safety, or as requested
by the patient. In these instances, the rt-PA will be discon-
tinued but patients will be followed for study outcomes
for the full six month study period. Reasons for discontin-
uation of study drug are outlined in Table 4.
Study withdrawal
Given that the primary and secondary outcomes require
the presence of a catheter, follow up for these outcomes
can only occur if the patient is alive, accessible for moni-
toring, and has a catheter in-situ. Therefore patients will
be censored and withdrawn from follow-up at the follow-
ing points in time: removal of the catheter (including acci-
dental removals and exchange over a guidewire); a non-
mechanical indication (such as catheter-related infection,
transfer to peritoneal dialysis, kidney transplantation,
maturation of permanent access, or withdrawal from ther-
apy); transfer of patient to another city which is not a sat-
ellite unit of the original study centre; and death.
Statistical analysis
Analysis of the primary and secondary outcomes will be
based on the intention-to-treat principle. Individual pri-
mary outcomes, in addition to the composite outcomes,
will be examined. The time from randomization until
catheter malfunction will be analyzed and Kaplan-Meier
estimates of the probability of event-free survival will be
calculated for the control and treatment arms. Cox pro-
portional hazards analysis will also be used to compare
event-free survival in the rt-PA and heparin groups, con-
trolling for clinical risk factors and including stratification
variables. A secondary on-treatment analysis will also be
undertaken. A planned subgroup analysis will be under-
taken stratified by catheter luminal volume. This analysis
will take into account the actual concentration of rt-PA the
patient received as the luminal volume, and thus rt-PA
concentration, may vary between patients.
The proportion of patients in each treatment arm achiev-
ing the secondary outcome, catheter-related bacteremia,
will be determined, as will the number of infections per
1000 catheter-days. Differences in proportions will be
assessed using the Fisher's exact test and the number of
infections per 1000 catheter days using the exact binomial
test. A secondary analysis to identify predictors of catheter
malfunction, including variables such as intra-dialysis
weight loss and catheter flow parameters, will also be con-
ducted.
Sample size considerations
Sample size calculations are based on dropout rates and
time to needing rt-PA for catheter malfunction as
observed at the University Health Network in Toronto,
Canada (C. Lok personal communication), as well as
reported by Little et al [13]. The following parameters
were used for the sample size calculations: annual drop-
out rate of 75%; one year event rate in the heparin arm of
95% and 98%; effect sizes of 30%, 33.3%, 35% and 40%;
power of 0.80; and an α-level of 0.05. Calculations were
done using simulations with 500 samples per condition,
and assuming the dropout rate was independent of the
Table 4: Reasons for Discontinuing Patient Study Drug
• Started anticoagulation therapy
• Major hemorrhage, defined as bleeding resulting in a drop in hemoglobin greater than 20 g/L or bleeding requiring blood transfusion with other 
clinical evidence or suspicion of bleeding
• Undergone major surgery
• Diagnosis of intraspinal or intracranial neoplasm
• Patient decision to withdraw
• Active pericarditis
• Missed two or more consecutive weekly study treatment sessions
Table 5: Number of patients per arm, based on effect size and failure rate
Effect Size Failure Rate 95% Failure Rate 98%
30% 235 195
33.3% 185 160
35% 160 140
40% 120 95BMC Nephrology 2006, 7:8 http://www.biomedcentral.com/1471-2369/7/8
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primary outcome. Simulations including virgin versus
non-virgin catheter status had no appreciable impact on
sample size estimates. Table 5 presents the number of
patients required per arm to detect specified risk reduc-
tions, at failure rates of 95% and 98% respectively. Given
these estimates a study size of 170 patients per arm was
chosen.
Cost-effectiveness analysis
The primary objective of the cost-effectiveness analysis is
to determine the incremental cost required to avoid place-
ment of a new hemodialysis catheter, assuming that pro-
phylactic rt-PA is an effective strategy in preventing
catheter malfunction. The secondary objectives are to
determine which locking solution, rt-PA versus heparin,
results in lower overall catheter-related costs and to deter-
mine the cost per month to maintain patency in a catheter
for patients randomized to rt-PA compared to those rand-
omized to heparin, after controlling for baseline covari-
ates.
The resources required to maintain the patency of a hemo-
dialysis catheter will include the following: the drug (ie rt-
PA or heparin); catheter-related hospitalizations (for cath-
eter-related bacteremia, associated complications of infec-
tions such as endocarditis and osteomyelitis and other
catheter-related indications such as bleeding following
catheter insertion); outpatient catheter-related infections;
and outpatient treatment of catheter malfunction (i.e, rt-
PA use and radiology procedures). The resources required
will be collected for patients at all sites. Given that the cost
of these resources may differ across sites, the cost of each
resource will be assessed in detail at one site (Calgary
Health Region). Drug costs will be obtained from the
local pharmacy and provincial drug benefit lists as appli-
cable. The cost of all other resources will be determined
using the cohort of patients receiving care at the Calgary
Health Region, using previously validated methodology
[32].
Next, using the perspective of a health care provider, an
economic evaluation, using decision analytic modeling,
will be performed to determine the impact of heparin and
rt-PA on costs and clinical outcomes (i.e, need for a new
hemodialysis catheter and patient months with a patent
catheter) and the cost required to avoid a new hemodial-
ysis catheter placement over a one-year time horizon. A
Markov process will be used to model monthly transitions
between the three possible clinical states, "functioning
catheter", "dysfunctional catheter" and death. The model
outputs will be avoidance of a new catheter placement,
patient months with a patent catheter, cost for each of the
treatment strategies, and the cost to avoid placement of a
new catheter for the use of rt-PA compared with heparin.
As described, although the number and type of resources
required to maintain patients with a functioning catheter
may be similar across the approximately 14 centres
involved in this study, the costs of these resources may dif-
fer. To increase the generalizability we will therefore
undertake a sensitivity analysis where the costs for cathe-
ter care related to hospitalizations and treatment of cath-
eter malfunction are more representative of individual
provinces, as well as other countries. This will be under-
taken by obtaining fee schedules from each of the prov-
inces represented in the study, as well as details regarding
costs of catheter care available in the published literature.
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